Pharma channel feed

Genen­tech yanks Gavre­to's rare thy­roid can­cer in­di­ca­tion, months be­fore hand­ing it back to Blue­print

Last year
FDA+

Aus­tralia re­clas­si­fies psy­che­delics to fa­cil­i­tate med­ical use, as ad­vo­cates push for sim­i­lar move in US

Last year
R&D

J&J leads phar­ma com­pa­nies in brand rank­ings, top­ping Roche, Bay­er and Pfiz­er amid over­all in­dus­try de­cline

Last year
Marketing

J&J tack­les med­ical il­lus­tra­tion in­equity with free data­base of di­verse im­ages

Last year
Marketing

Am­gen and Hori­zon call FTC's at­tempt to block $28B merg­er un­con­sti­tu­tion­al in coun­ter­claims

Last year
Law

J&J will ad­vance pso­ri­a­sis drug li­censed from Pro­tag­o­nist af­ter fuller Phase IIb read­out

Last year
R&D

Di­ver­si­ty of Hu­mi­ra biosim­i­lar launch­es re­veals the dif­fi­cul­ty of de­thron­ing Ab­b­Vie's megablock­buster

Last year

Re­vance Ther­a­peu­tics push­es Botox 'breakup' in lat­est cam­paign for ri­val cos­met­ic drug

Last year
Marketing

Eu­ro­pean Com­mis­sion so­lid­i­fies vac­cine man­u­fac­tur­ing plans to pre­pare for fu­ture health emer­gen­cies

Last year
Coronavirus

All eyes on Brent Saun­ders: Bausch + Lomb deal­mak­er to buy Xi­idra from No­var­tis in $1.75B deal

Last year
Deals

Au­rinia will ex­plore pos­si­ble sale, fol­low­ing push by share­hold­er

Last year
Deals

Judge in Astel­las patent suit de­nies mo­tion to bol­ster de­fen­dant’s case

Last year
Law

Alvotech re­ceives an­oth­er CRL from the FDA for Hu­mi­ra biosim­i­lar can­di­date

Last year
FDA+
Manufacturing

FTC and DOJ pro­pose changes that could slow deal­mak­ing re­view process

Last year
Deals

Up­dat­ed: Bio­Marin’s he­mo­phil­ia A gene ther­a­py Roc­ta­vian wins FDA ap­proval af­ter de­lay and re­jec­tion, priced at $2.9M

Last year
FDA+

Eli Lil­ly to buy di­a­betes cell ther­a­py part­ner Sig­ilon, ex­pand­ing bet on pre­clin­i­cal pro­gram

Last year
Deals
Cell/Gene Tx

Sanofi hints at 'class ef­fec­t' for mR­NA flu shot as it un­veils vac­cine R&D plans dri­ven by $3.2B deal

Last year
R&D

FDA ad­comm votes in fa­vor of Ipsen's fi­brodys­pla­sia drug

Last year
R&D

ICER taps new pres­i­dent as Steve Pear­son an­nounces plans to step down

Last year
People

Gilead sup­ports cre­ation of on­line re­source hub for Black pa­tients with triple-neg­a­tive breast can­cer

Last year
Marketing

Af­ter CRL in 2022, Pfiz­er and OP­KO get FDA nod for pe­di­atric growth hor­mone de­fi­cien­cy med

Last year
FDA+

As­traZeneca ex­pands tree-plant­i­ng ini­tia­tive with an­oth­er $400M to plant 200M trees by 2030

Last year

FDA, EMA ac­cept Pfiz­er's he­mo­phil­ia B gene ther­a­py, set­ting up show­down with CSL Behring

Last year
FDA+

UK’s NICE wants more ef­fec­tive­ness da­ta on Lil­ly’s tirzepatide

Last year
First page Previous page 117118119120121122123 Next page Last page
A service from the Financial Times